The Annual General Meeting for 2009  for NorDiag ASA was held  today. The Minutes  from  the  General  Meeting,  including  a  register  of shareholders present,  is attached. A total  of 63,4%  of the  share capital and voting rights was represented. All resolutions made  were in accordance with  the recommendations from  the Board of  Directors and the Nomination Committee.

The General  Meeting  approved the  Annual  Accounts and  the  Annual Report for the financial  year of 2008, as  proposed by the Board  of Directors, including the covering of loss.

It was further  resolved to carry  out a share  consolidation in  the ratio of 10:1 by increasing the nominal value of the shares with  NOK 0.90 from NOK 0.10  to NOK 1.00, so  that 10 shares are  consolidated into 1. This caused the requirement for a share issue of 4 new shares prior to the  consolidation, in order  to achieve a  round number  of shares. For practical reasons the  General Meeting resolved that  the shareholders' preferential rights to the 4 new shares were waived.

The share issue of four new  shares will be carried out  immediately. However, based on normal progress, it  is expected that it will  take up to  two  weeks  until  the share  issue  is  registered  with  the Norwegian Register of Business Enterprises.

When the share  issue is  registered with the  Norwegian Register  of Business Enterprises,  the share  consolidation will  immediately  be reported to the  Norwegian Register of  Business Enterprises and  VPS through the  company's registrar.  The  share consolidation  will  be effective with respect to trading in the company's shares as soon  as feasible following  the  registration of  the  share issue  with  the Norwegian Register of Business Enterprises.

The normal lag in VPS is three working days. This means that it  will take three  working  days  from  the  company  notifies  VPS  of  the resolution of a share consolidation until this share consolidation is reflected in the VPS/shareholder register and hence is completed. The share  consolidation  will  then  affect  those  persons  which   are registered as shareholders at the time of implementation of the share consolidation, and e.g. not those  registered as shareholders at  the time of the  resolution by  the General Meeting  regarding the  share consolidation.

As a result of the share consolidation, the number of shares will  be reduced  from  120,651,690  to  12,065,169.  Some  of  the  company's shareholders have shareholdings which are not  divisible by 10,  and these will be rounded  upwards to the nearest  whole share after  the consolidation. Furthermore,  the  company  has  agreed  with  certain shareholders that  they  will  free  of  compensation  surrender  the necessary number of shares to complete the rounding process.

As the company has outstanding warrants it was resolved to  implement a  consolidation  of  the   warrants,  corresponding  to  the   share consolidation, so  that 10  warrants are  consolidated into  1.   The procedure for the  consolidation of  warrants is equal  to the  share consolidation. Through the consolidation  of warrants, the number  of  3,860,706, while  the  number  of C-warrants  will  be  reduced  from 4,080,000  to  408,000.  For  further  information  related  to   the consolidation of warrants, reference is made to the attached  Minutes and the notice dated 15 April 2009.

Other resolutions made at the  General Meeting include the  reduction of the share premium fund.  Furthermore, Mr Hans Hekland was  elected as Deputy Chairman of the Board of Directors. Besides this  election, the composition of the Board of  Directors is unchanged, as no  Board members were up for election.

Contact:
CFO Tone Kvåle, phone +47 915 19576.

About NorDiag: NorDiag is a biotechnology company developing, manufacturing and marketing automated solutions, instruments and tests, for use in diagnostic of infectious diseases and cancer. The Company`s core competence is isolation of bacterial and human DNA from difficult clinical samples, and the Company has established a solid market share in the Scandinavian market for sexually transmitted infections. The company has similar applications for Tuberculosis, MRSA and DNA from stool. Applications for respiratory pathogens and viruses are under development. NorDiag was founded in 2003 and has its headquarters in Oslo - Norway. The Company has offices and laboratories in Stockholm - Sweden and West Chester (PA) - USA. The group has 36 employees. NorDiag is listed on Oslo Stock Exchange with the ticker NORD.

For further information - www.nordiag.com.

Read the notice and the protocol here.

Read the notice and the protocol in Norwegian here.